

We've known since early on in the pandemic that COVID reinfections could occur. One of the first reinfections reported was in a 33-year-old man from Hong Kong. His initial infection was diagnosed on March 26 2020, with his second infection, with a genetically distinct virus, being diagnosed 142 days later.

Since then reports of reinfection have become common, especially since the emergence of the omicron variant. Early research from South Africa suggests that the risk of reinfection increased quickly and substantially after the variant arrived.

So why are reinfections increasing? The simple answer is because our immunity is often no longer sufficient to prevent an infection. This can be due to the appearance of a new viral variant like omicron that, because of mutations to its form, is less recognisable to the immune system, meaning the virus bypasses prior immunity. Or it can be because immunity has waned since we were last infected or vaccinated. We know that this is a particular issue with COVID immunity hence the need for vaccine boosters.

Plus, as discussed previously, the coronavirus almost always enters the human body via the nose and throat. Immunity in the mucosal linings of these areas tends to be relatively short lived compared to systemic immunity throughout the body. This may explain why protection against severe illness, usually rooted in the lungs, lasts longer than protection against infection.

How common are reinfections? The UK has recently started publishing data on reinfections on its COVID dashboard. It classifies a reinfection as someone receiving a new positive COVID test result more than 90 days after their last infection.

Up to February 6 2022, there had been over 14.5 million primary infections and around 620,000 reinfections in England so one reinfection for every 24 primary infections. Over 50 per cent of all reinfections have been reported in since December 1 2021, suggesting again that the risk of reinfection has increased substantially with omicron.

The UK's Office for National Statistics (ONS) also measures reinfections, although does so differently. For someone to count as being reinfected, there needs to be 120 days or four consecutive negative PCR tests between the positive tests confirming their two cases. The ONS suggests that the rate of reinfection has increased 15-fold since the arrival of omicron, and that currently reinfections account for about 10 per cent of all infections reported in England, compared to just one per cent during November 2021.

The 90- or 120-day gap will undoubtedly miss some reinfections that occur sooner. Plus, by comparing daily recorded case numbers with estimates of how much of the population is infected with the virus at any given point in time, it appears around half of primary infections are never diagnosed. Many reinfections are therefore likely to be incorrectly categorised as primary ones. Also, if reinfections are generally milder, a higher proportion are likely to be undiagnosed.

But are reinfections milder? Primary infections

Health Matters



New COVID mutants increase risk of reinfection

in vaccinated people (who have some COVID immunity) are generally less severe than primary infections in unvaccinated people (who don't have any immunity) this is why hospitalisation rates are lower among the vaccinated.

It's reasonable therefore to assume that, in general, reinfections should be less severe than primary infections, as the person being reinfected will have some pre-existing immunity from their primary infection. Plus, many people

will have been vaccinated between their infections, which will have further raised their levels of immunity.

And even though immunity against being infected by the coronavirus and developing COVID symptoms wanes, protection against severe disease and death appears much more durable. So at the extreme end of things, reinfections definitely seem to be less severe.

(Paul Hunter, University of East Anglia Norwich)

Exercise post-vaccine bumps up antibodies

Researchers at Iowa State University found 90 minutes of mild to moderate-intensity exercise directly after a flu or COVID-19 vaccine may provide an extra immune boost.

In the newly published study, participants who cycled on a stationary bike or took a brisk walk for an hour-and-a-half after getting a jab produced more antibodies in the following four weeks compared to participants who sat or continued with their daily routine post-immunization. The researchers found similar results when they ran an experiment with mice and treadmills.

Antibodies are essentially the body's "search and destroy" line of defense against viruses, bacteria, fungi and parasites. Vaccines help the immune system learn how to identify something foreign and respond by bolstering the body's defenses, including an increase in antibodies.

"Our preliminary results are the first to demonstrate a specific amount of time can enhance the body's antibody response to the Pfizer-BioNtech COVID-19 vaccine and two vaccines for influenza," said Kinesiology Professor Marian Kohut, lead author of the paper published in the journal Brain, Behavior, and Immunity.

The researchers said the study's findings could directly benefit people with a range of fitness levels. Nearly half of the participants in the experiment had a BMI in the

overweight or obese category. During 90 minutes of exercise, they focused on maintaining a pace that kept their heart rate around 120-140 beats per minute rather than distance.

In the study, the researchers also tested whether participants could get the same bump in antibodies with just 45-minutes of exercising. They found the shorter workout did not increase the participants' antibody levels. Kohut said the research team may test whether 60 minutes is enough to generate a response in a follow-up study.

As to why prolonged, mild to moderate-intensity exercise could improve the body's immune response, Kohut said there may be multiple reasons. Working out increases blood and lymph flow, which helps circulate immune cells. As these cells move around the body, they're more likely to detect something that's foreign.

Data from the mouse experiment also suggested a type of protein (i.e., interferon alpha) produced during exercise helps generate virus-specific antibodies and T-cells.

"But a lot more research is needed to answer the why and how. There are so many changes that take place when we exercise -- metabolic, biochemical, neuroendocrine, circulatory. So, there's probably a combination of factors that contribute to the antibody response we found in our study," said Kohut.



TULSYAN NEC LIMITED
 Regd. Off. : 1st Floor, Apex Plaza, 3, Nungambakkam High Road, Chennai - 600 034. Phone : 044 - 6199 1066.
 Fax : 044 - 6199 1066. Email : investor@tulsyanec.in
 Website : www.tulsyanec.in CIN No. : L28920TN1947PLC007437

Extract of Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine Months ended December 31, 2021 under Ind AS

Sl. No.	Particulars	Standalone			Consolidated		
		Quarter ended December 31, 2021 (Unaudited)	Year to date figures December 31, 2021 (Unaudited)	Previous quarter ended December 31, 2020 (Unaudited)	Quarter ended December 31, 2021 (Unaudited)	Year to date figures December 31, 2021 (Unaudited)	Previous quarter ended December 31, 2020 (Unaudited)
1.	Total Income from Operations	15,877.78	51,555.95	15,213.33	18,487.98	58,696.88	17,350.63
2.	Net Profit/(Loss) for the period (before tax and exceptional items)	(2,143.69)	(2,741.95)	(4,719.38)	(2,147.53)	(2,579.99)	(4,582.99)
3.	Net Profit/(Loss) for the period before tax (after exceptional items)	(2,181.02)	41,412.13	(4,719.38)	(2,184.87)	41,574.09	(4,582.99)
4.	Net Profit/(Loss) for the period after tax (after exceptional items)	(2,181.02)	41,412.13	(4,719.38)	(2,184.87)	41,574.09	(4,582.99)
5.	Other comprehensive income (net of tax)	(20.44)	(61.32)	(5.27)	(20.44)	(61.32)	(5.27)
6.	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other comprehensive income (after tax))	(2,201.46)	41,350.81	(4,724.65)	(2,205.31)	41,512.77	(4,588.26)
7.	Equity Share Capital (face Value of Rs.10 per share)	1,471.38	1,471.38	1,471.38	1,471.38	1,471.38	1,471.38
8.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year						
9.	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)	(14.82)	281.45	(32.07)	(14.85)	282.55	(31.15)
	(a) Basic	(14.82)	281.45	(32.07)	(14.85)	282.55	(31.15)
	(b) Diluted						

NOTES:
 1. The above results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board Of Directors at their meeting held on February 14, 2022.
 2. The statement has been prepared in accordance with the companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
 3. The above is an extract of the detailed format of the unaudited financial results for the quarter and Nine months ended December 31, 2021 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Obligations Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Financial Results for the Quarter and Nine months ended December 31, 2021 are available on the website of the BSE Limited i.e. www.bseindia.com, on the Stock Exchange where the Company's shares are listed and on the website of the Company i.e., www.tulsyanec.in
 4. The previous year figures have been regrouped/re-classified wherever necessary.

for Tulsyan NEC Limited
 Sd/-
 Sanjay Tulsyan
 Managing Director
 DIN : 00632802

Place : Chennai
 Date : 14th February, 2022

NAME CHANGE
 I, Thendral Venkata Selvan, D/o: Selvan.T.V., Date of Birth: 24.09.1996, Residing at No.E111, 16th Cross Street, Besant Nagar, Chennai - 600090, shall henceforth be known as **THENDRAL SELVAN**

Thendral Venkata Selvan

NAME CHANGE
 I, Kusi Muhamadhu Ali Mohamadhu Faruk, S/o. Mohamed Ali, Date of Birth: 12.07.1974, Residing at No.56, Jannath Nagar, Singaraaveethi, Lalpettai Post, Cuddalore Dist - 608303, shall henceforth be known as **Mohamad Ali Mohamed Faruk**.

Kusi Muhamadhu Ali Mohamadhu Faruk

CHANGE OF NAME
 I, RAJESWARI alias **EASWARI** W/o.Sedhulingam Date of Birth : 01.04.1968 Place of Birth:Thiruvallavaya Nallur Residing at No.3/33, Nethaji Street, Thirumalai Nagar, Ramapuram, Chennai - 600 089 Shall henceforth be known as **S.RAJESWARI RAJESWARI alias EASWARI**

NAME CHANGE
 I, Suresh Nawin ayyammal Seeni, S/o. Seeni Naiduk, Date of Birth: 27.07.1984, Residing at No.1/29, 1st Block, 1st Main Road, Kaviarasu Kannadhasan Nagar, Kodungaiyur, Chennai - 600 118, shall henceforth be known as **SANKAR SEENI NAIDU**, Suresh Nawin ayyammal Seeni

CHANGE OF NAME
 I, **DILIPKUMAR PURUSOTHAMAN**, Son of Thiru. Purusothaman Born on 30th July 1992, (Native District:- Chennai), residing at Block E-83, Golden Fortune Apts, Nalambur 1st Main Road, Nalambur, Tiruvallur,Tamilnadu-600 095, shall henceforth be known as **DILIP KUMAR PURUSHOTHAMAN**

CITY UNION BANK LIMITED
 ADMINISTRATIVE OFFICE-SHARES "NARAYANA"
 24B Gandhi Nagar, Kumbakonam - 612 001
 Phone No : 0435 - 240232/9361 703585
 E-mail : shares@cityunionbank.com
 Website : http://www.cityunionbank.com
 CIN: L65110TN1904PLC001287

NOTICE FOR LOSS OF SHARE CERTIFICATE(S)

Notice be and is hereby given cautioning all the shareholders/public not to deal in any manner in respect of below mentioned securities of the Bank as the same have been informed to the Bank by the shareholder(s) as lost/misplaced (with or without transfer deeds).

Folio No.	Certificate No.(s)	Certificate Shares	Distinctive No.(s)	Name
3290	3290	1000	14243351 - 14244350	M V RAJENDRA SAH
100867	105041 229607	735 73	421014076- 421014810 659143237- 659143309	GEETHA RAMADOSS

Any person who has any claim in respect of the aforesaid Share Certificates should lodge such claim with the Bank at its Administrative office/Registrar & Share Transfer Agents "RTA" at M/s Integrated Registry Management Services Private Limited, Unit: City Union Bank Ltd., 2nd Floor, Kences Towers, No.1, Ramakrishna Street, North Usman Road, T Nagar, Chennai - 600 017, within 15 days of publication of this notice, after which no claim will be entertained and the Bank will proceed to issue the Duplicate Share Certificates in favour of the Registered Holder(s).

Place : Kumbakonam
 Date : 14/02/2022
 For City Union Bank Limited
 Company Secretary

SPEL Semiconductor Limited
 Registered Office & Factory : 5 CMDA Industrial Estate, MM Nagar (Chennai) 603 209
 CIN: L32201TN1984PLC011434 EMail: info@spel.com website: www.spel.com

[Regulation 47(1)(b) of the SEBI (LODR) Regulations, 2015]

Extract of Statement of Unaudited Financial Results for the Quarter and Half Year Ended December 31, 2021

Sl. No.	Particulars	Quarter Ended		Year to date Ended		Year Ended
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.03.2021
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Total Income from Operations	321.49	283.66	450.49	690.70	1592.11
2.	Net Profit/(Loss) for the period (Before Tax and/or Exceptional items)	(161.11)	(165.16)	(107.81)	(684.07)	(564.25)
3.	Net Profit/(Loss) for the period before Tax (after Exceptional items)	(161.11)	(165.16)	(107.81)	(684.07)	(844.23)
4.	Net Profit/(Loss) for the period after Tax (after Exceptional items)	(103.11)	(173.36)	(90.38)	(638.60)	(863.50)
5.	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	(62.17)	(132.41)	(79.88)	(515.78)	(699.74)
6.	Equity Share capital	4613.25	4613.25	4613.25	4613.25	4613.25
7.	Other Equity as shown in the Audited Balance Sheet of the previous year.					2590.85
8.	Earnings per share (of Rs. 10/- each) for continuing and discontinued operations : Basic and Diluted	(0.22)	(0.38)	(0.20)	(1.38)	(1.87)

Note
 The above is an extract of the detailed format of the unaudited Financial Results of the Company for the quarter and half year ended Dec 31,2021 filed with the Bombay Stock Exchange (BSE) under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015 as amended. The full format of the Financial Results is available on the BSE website (www.bseindia.com) and Company's website (www.spel.com).

Date: February 14, 2022
 Place: Chennai

For and on behalf of the Company
 D. Balakrishnan
 Director & CEO

Upasana Finance Limited
 Regd Off: Sapna Trade Centre, 10th Floor, 10B/2 No. 109, PH Road, Chennai - 600084
 Email ID: upasana_shares@yahoo.com
 CIN: L65191TN1985PLC011503

Statement of Unaudited Financial Results for the Quarter and Nine Months ended 31st December 2021

S.No	Particulars	Quarter Ended			Nine Months Ended		Prev Yr Ended
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from Operations	34.83	55.54	22.61	126.75	60.61	61.39
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	12.14	40.95	15.78	84.31	38.51	53.86
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	12.14	40.95	15.78	84.31	38.51	53.86
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items)	9.08	30.64	11.68	63.09	28.50	48.07
5	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	9.08	30.64	11.68	63.09	28.50	48.07
6	Equity Share Capital	427.80	427.80	427.80	427.80	427.80	427.80
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet for the year ended 31st March 2021	0	0	0	0	0	0
8	Earnings Per Share (of Rs.10/- each)(for continuing and discontinued operations): 1. Basic: 2. Diluted:	0.21 0.21	0.72 0.72	0.27 0.27	1.47 1.47	0.67 0.67	1.12 1.12

Note:
 1. The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full formats of the Quarterly Financial Results are available on the website of the Stock Exchange www.bseindia.com and on the Company's website www.ulfindia.com
 2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 14, 2022.

Place: Chennai
 Date: February 14, 2022

For UPASANA FINANCE LIMITED
 Sd/-
 Bhavika M Jain
 Director